Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas

Inclusion Criteria: Adult participants (greater than or equal to 18 years old): * Histologically confirmed de novo (primary) glioblastoma with unequivocal tumor progression or recurrence. * In case of testing at the time of first progression: either at least 3 months after the end of radiotherapy or have tumor progression that is clearly outside the radiation field or have tumor progression unequivocally proven by surgery/biopsy * Absence of any psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule; such conditions should be assessed with the patient before registration in the trial. * Availability of adequate biological material (formalin-fixed paraffin embedded \[FFPE\] tumor) for central testing of Epithelial Growth Factor Receptor (EGFR) amplification * Presence of EGFR amplification confirmed by central assessment; participants with undetermined EGFR status are excluded * World Health Organization (WHO) Performance status 0 - 2 * No more than one line of chemotherapy (concurrent and adjuvant Temozolomide based chemotherapy including in combination with another investigational agent is considered one line of chemotherapy). Chemotherapy must have been completed at least 4 weeks prior to randomization. * Post surgery MRI within 48 hours following surgery, however an MRI scan has to be done within 2 weeks prior to randomization. * Surgery completed at least 2 weeks before randomization …